Center for Cancer Research, Lymphoid Malignancies Branch, Multiple Myeloma Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Center for Cancer Research, Lymphoid Malignancies Branch, Multiple Myeloma Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Semin Oncol. 2022 Feb;49(1):48-59. doi: 10.1053/j.seminoncol.2022.01.008. Epub 2022 Jan 20.
Daratumumab, a human IgG1 kappa monoclonal antibody targeting CD38 has transformed the treatment paradigm of multiple myeloma (MM). With the identification of CD38 as a crucial receptor involved in immune system function, it became an ideal target for monoclonal antibody (mAb) drug development in MM. Daratumumab's unique multifaceted mechanism of action has led to great success in the treatment of relapsed refractory multiple myeloma (RRMM) as well as newly diagnosed multiple myeloma (NDMM) patients. Along with its efficacy comes a low toxicity profile, improved further with the introduction of subcutaneous daratumumab. With such success within MM, daratumumab is now being explored in other disease states. This article will review daratumumab's drug development, practical use, and future potential indications.
达雷妥尤单抗是一种针对 CD38 的人源 IgG1κ 单克隆抗体，改变了多发性骨髓瘤（MM）的治疗模式。随着 CD38 被确定为参与免疫系统功能的关键受体，它成为 MM 中单克隆抗体（mAb）药物开发的理想靶点。达雷妥尤单抗独特的多效作用机制使其在治疗复发难治性多发性骨髓瘤（RRMM）和新诊断的多发性骨髓瘤（NDMM）患者方面取得了巨大成功。其疗效确切，且毒性低，皮下注射达雷妥尤单抗进一步降低了毒性。由于在 MM 中取得了如此成功，达雷妥尤单抗现在正在其他疾病领域进行探索。本文将综述达雷妥尤单抗的药物研发、实际应用及未来的潜在适应证。
